DrugPatentWatch

DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.

Generic Name: cephalexin

Summary for Generic Name: cephalexin

Tradenames:5
Patents:0
Applicants:22
NDAs:55
Drug Master File Entries: see list29
Suppliers: see list2
Therapeutic Class:Antibacterials

Clinical Trials for: cephalexin

Bioequivalence Study of Cephalexin Tablets 1g
Status: Completed Condition: Infections, Respiratory Tract

Bioequivalence Study of Cephalexin Suspension 125
Status: Completed Condition: Infections, Respiratory Tract

Bioequivalence Study of Cephalexin Suspension 250
Status: Completed Condition: Infections, Respiratory Tract

Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
Status: Recruiting Condition: Cellulitis

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
Status: Completed Condition: Staphylococcal Infection; Abscess; Staphylococcal Skin Infection; Folliculitis

Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
Status: Completed Condition: Anti-Infective Agents

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules
Status: Completed Condition: Anti-Infective Agents

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
Status: Completed Condition: Anti-Infective Agents

A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections
Status: Completed Condition: Mild to Moderate Uncomplicated Skin and Skin Structure Infections

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
Status: Terminated Condition: Bladder Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist_Flag Patent Expiration Exclusivity Expiration
Lilly
KEFTAB
cephalexin hydrochloride
TABLET; ORAL050614Oct 29, 1987DISCNNo<disabled><disabled>
Lilly
KEFTAB
cephalexin hydrochloride
TABLET; ORAL050614May 16, 1988DISCNNo<disabled><disabled>
Lilly
KEFLET
cephalexin
TABLET; ORAL062745Dec 1, 1986DISCNNo<disabled><disabled>
Lilly
KEFLET
cephalexin
TABLET; ORAL050440Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
The preview shows a limited data set. Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Sign up for a free trial

First name
Last name
Email address

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639

`abc